Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The NIH Clinical Collection and NIH Clinical Collection 2


The NCC consists almost entirely of drugs that have been in phase I-III clinical trials and have not been represented in other arrayed collections. These compounds also have favourable attributes for inclusion in a screening collection, such as purity, solubility and commercial availability for re-supply.
The collections contain 450 and 281 compounds, respectively arrayed in six 96-well plates at 10 mM solution in 100% DMSO.

DTP Approved Oncology Drugs Set



A set of 89 FDA-approved anticancer drugs to enable cancer research. Contains most of the current FDA-approved anticancer drugs arrayed into a 96 well plate. Compounds are available at 10mM in 100% DMSO

DTP Mechanistic Diversity Set


The mechanistic diversity set consists of 879 compounds representing a broad range of growth inhibition patterns focused on distinct activity clusters. These are arrayed into 96 well plate format.

DTP Diversity Sets I and II


(Now superceded by Diversity Sets III and IV which are NOT held within the TDI; however we may be able to to supplement ANY library with additional compounds of interest.

Diversity Set I contains 1990 compounds; (Diversity Set II slighlty less) representative of the chemical diversity of the >140,000 chemicals available for testing at 10mM in 100% DMSO.

GSK Published Kinase Inhibitor Set


A set of 367 inhibitors published by GSK covering >20 chemotypes. Available to any academic investigator with structures and selectivity data. Investigators using this set are required to deposit data in the public domain ( is the suggested site)

Sigma Aldrich LOPAC1280


1,280 pharmacologically active compounds covering all major target classes (Kinases, Proteases, GPCR's etc). The library contains marketed drugs and pharmaceutically relevant compound structures, providing predictable activity profiles against a wide range od drug targets.

The LOPAC library is easily searchable using the following web tool.

MicroSource Discovery Systems



The PHARMAKON 1600 library is a collection of 1600 known drugs from US and International Pharma. All compounds within the PHARMAKON 1600 Collection have reached clinical evaluation and demonstrated biological activity against known targets. Many of the drugs represented in the library are available on the market.

ChemBridge's DIVERSetTM


A library collection of 50,000 diverse structure compounds for primary screening; the libraries are designed to provide the greatest coverage of pharmacophore space within 50,000 compounds while maintaining structural diversity.

SelleckChem Bioactive Compound Library

A structurally diverse, unique collection of 1902 bioactive compounds for primary screening. Library includes Selleck inhibitors, active pharmaceutical ingredients, natural products and chemotherapeutic agents. Bioactivity and safety profiled in pre-clinical and clinical settings - some with FDA approval; citations and reviews available for screening library.


TDI Small Molecule Probe Library


The TDI Small Molecular Probe Library is a novel, specially designed collection of compounds chosen to explore complex disease pathways and to assist in the characterization of disease targets. The compounds are being carefully chosen to fulfil a set of stringent criteria. This library is currently under construction (should number between 3000 and 4000 compounds when complete) and will become the backbone of the small compound libraries we will utilize at the Target Discovery Institute.

TDI Expanded Oncology Drug Set

The TDI Expanded Oncology Drug Set is a novel, specially designed set of 222 anti-cancer compounds arrayed into 96 and 384 well plates.  The library was designed in colaboration with FIMM and the SGC to contain both experimental and approved oncology specific compounds for drug screening and target discovery.

TDI Epigenetics Library


The TDI Epigenetics Library is a novel set of 116 small compounds created in collaboration with Oxfords SGC. Designed to explore epigenetic interactions in complex disease pathways to elucidate disease targets. The library includes a broad range of potent inhibitors of epigenetic targets and is available in 96 well and 384 well format; including ECHO ready plates.